FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306651447> ?p ?o ?g. }

• W4306651447 endingPage "5078" @default.
• W4306651447 startingPage "5078" @default.
• W4306651447 abstract "Immunotherapy with immune checkpoint blockers (ICB) represents a valid therapeutic option in older patients for several solid cancer types. However, most of the data concerning efficacy and adverse events of ICB available are derived from younger and fitter patients. Reliable biomarkers are needed to better select the population that will benefit from ICB especially in older patients who may be at a higher risk of developing immune-related adverse events (irAEs) with a greater impact on their quality of life. The Lung Immune Prognostic Index (LIPI) is a score that combines pretreatment dNLR (neutrophils/[leukocytes − neutrophils]) and lactate dehydrogenase (LDH) and is correlated with outcomes in patients treated with ICB in non-small-cell lung cancer. We aimed to assess the impact of LIPI in ICB outcomes in a dedicated cohort of older patients. The primary objective was to study the prognostic role of LIPI score in patients aged 70 years or above in a real-life population treated with anti-programmed death-(ligand)1 (anti PD-(L)1). dNLR and LDH were collected in a prospective cohort of patients aged 70 years or above treated with PD-(L)1 inhibitors with metastatic disease between June 2014 and October 2017 at Gustave Roussy. LIPI categorizes the population into three different prognostic groups: good (dNLR ≤ 3 and LDH ≤ ULN—upper normal limit), intermediate (dNLR > 3 or LDH > ULN), and poor (dNLR > 3 and LDH > ULN). Anti PD-(L)1 benefit was analyzed according to overall survival (OS), progression free survival (PFS), and overall response rate (ORR) using RECIST v1.1. criteria. In the 191 older patients treated, most of them (95%) were ICB-naïve, and 160 (84%) had an ECOG performance status of 0−1 with a median age at ICB treatment of 77 (range, 70−93). The most common tumor types were melanoma (66%) and non-small-cell lung cancer (15%). The median follow-up duration was 18.8 months (95% CI 14.7−24.2). LIPI classified the population into three different groups: 38 (23%) patients had a good LIPI score, 84 (51%) had an intermediate LIPI score, and 43 (26%) had a poor LIPI score. The median OS was 20.7 months [95% CI, 12.6−not reached] compared to 11.2 months [95% CI, 8.41−22.2] and 4.7 months [95% CI, 2.2−11.3] in patients with a good, intermediate, and poor LIPI score, respectively (p = 0.0003). The median PFS was 9.2 months [95% CI, 6.2−18.1] in the good LIPI group, 7.2 months [95% CI, 5.4−13] in the intermediate LIPI group, and 3.9 months [95% CI, 2.3−8.2] in the poor LIPI group (p = 0.09). The rate of early death (OS < 3 months) was 37% in the poor LIPI group compared to 5% in the good LIPI group (<0.001). Poor LIPI score was associated with a poorer outcome in older patients treated with anti PD-(L)1. LIPI is a simple and accessible worldwide tool that can serve as a prognostic factor and can be useful for stratification benefit from ICB." @default.
• W4306651447 created "2022-10-18" @default.
• W4306651447 creator A5009978511 @default.
• W4306651447 creator A5017516888 @default.
• W4306651447 creator A5023794502 @default.
• W4306651447 creator A5026708002 @default.
• W4306651447 creator A5028596081 @default.
• W4306651447 creator A5028963681 @default.
• W4306651447 creator A5038686648 @default.
• W4306651447 creator A5038956527 @default.
• W4306651447 creator A5058348710 @default.
• W4306651447 creator A5060793722 @default.
• W4306651447 creator A5060937374 @default.
• W4306651447 creator A5065206480 @default.
• W4306651447 creator A5082291642 @default.
• W4306651447 creator A5086593040 @default.
• W4306651447 creator A5090082356 @default.
• W4306651447 date "2022-10-17" @default.
• W4306651447 modified "2023-10-09" @default.
• W4306651447 title "Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score" @default.
• W4306651447 cites W1776803469 @default.
• W4306651447 cites W1940241680 @default.
• W4306651447 cites W2019751406 @default.
• W4306651447 cites W2129155846 @default.
• W4306651447 cites W2152897456 @default.
• W4306651447 cites W2167333057 @default.
• W4306651447 cites W2191709890 @default.
• W4306651447 cites W2222086386 @default.
• W4306651447 cites W2288908606 @default.
• W4306651447 cites W2319895843 @default.
• W4306651447 cites W2527905628 @default.
• W4306651447 cites W2553059833 @default.
• W4306651447 cites W2554618897 @default.
• W4306651447 cites W2559804019 @default.
• W4306651447 cites W2560367415 @default.
• W4306651447 cites W2582788200 @default.
• W4306651447 cites W2592144107 @default.
• W4306651447 cites W2673218446 @default.
• W4306651447 cites W2784283849 @default.
• W4306651447 cites W2891266481 @default.
• W4306651447 cites W2898019549 @default.
• W4306651447 cites W2911182523 @default.
• W4306651447 cites W2916451481 @default.
• W4306651447 cites W2916611783 @default.
• W4306651447 cites W2925446385 @default.
• W4306651447 cites W2949640269 @default.
• W4306651447 cites W2987711192 @default.
• W4306651447 cites W2995533566 @default.
• W4306651447 cites W3010228464 @default.
• W4306651447 cites W3010387889 @default.
• W4306651447 cites W3027304337 @default.
• W4306651447 cites W3033353648 @default.
• W4306651447 cites W3054871167 @default.
• W4306651447 cites W3121555372 @default.
• W4306651447 cites W3159980941 @default.
• W4306651447 doi "https://doi.org/10.3390/cancers14205078" @default.
• W4306651447 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36291861" @default.
• W4306651447 hasPublicationYear "2022" @default.
• W4306651447 type Work @default.
• W4306651447 citedByCount "5" @default.
• W4306651447 countsByYear W43066514472023 @default.
• W4306651447 crossrefType "journal-article" @default.
• W4306651447 hasAuthorship W4306651447A5009978511 @default.
• W4306651447 hasAuthorship W4306651447A5017516888 @default.
• W4306651447 hasAuthorship W4306651447A5023794502 @default.
• W4306651447 hasAuthorship W4306651447A5026708002 @default.
• W4306651447 hasAuthorship W4306651447A5028596081 @default.
• W4306651447 hasAuthorship W4306651447A5028963681 @default.
• W4306651447 hasAuthorship W4306651447A5038686648 @default.
• W4306651447 hasAuthorship W4306651447A5038956527 @default.
• W4306651447 hasAuthorship W4306651447A5058348710 @default.
• W4306651447 hasAuthorship W4306651447A5060793722 @default.
• W4306651447 hasAuthorship W4306651447A5060937374 @default.
• W4306651447 hasAuthorship W4306651447A5065206480 @default.
• W4306651447 hasAuthorship W4306651447A5082291642 @default.
• W4306651447 hasAuthorship W4306651447A5086593040 @default.
• W4306651447 hasAuthorship W4306651447A5090082356 @default.
• W4306651447 hasBestOaLocation W43066514471 @default.
• W4306651447 hasConcept C121608353 @default.
• W4306651447 hasConcept C126322002 @default.
• W4306651447 hasConcept C141071460 @default.
• W4306651447 hasConcept C143998085 @default.
• W4306651447 hasConcept C159110408 @default.
• W4306651447 hasConcept C167135981 @default.
• W4306651447 hasConcept C181199279 @default.
• W4306651447 hasConcept C197934379 @default.
• W4306651447 hasConcept C2776256026 @default.
• W4306651447 hasConcept C2777318727 @default.
• W4306651447 hasConcept C2777701055 @default.
• W4306651447 hasConcept C2779951463 @default.
• W4306651447 hasConcept C2908647359 @default.
• W4306651447 hasConcept C55493867 @default.
• W4306651447 hasConcept C71924100 @default.
• W4306651447 hasConcept C72563966 @default.
• W4306651447 hasConcept C86803240 @default.
• W4306651447 hasConcept C99454951 @default.
• W4306651447 hasConceptScore W4306651447C121608353 @default.
• W4306651447 hasConceptScore W4306651447C126322002 @default.

• next